NASDAQ · KALV
Healthcare · Biotechnology
$27.00
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 1:06 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
KALV does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning KALV.
KALV research
Company profile and research snapshot.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 30, 2026 | Needham | Hold | — |
| Mar 26, 2026 | Stifel | Buy | — |
| Mar 26, 2026 | Citizens | Market Outperform | — |
| Mar 25, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Jun 4, 2026
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Mar 4, 2026
FRAMINGHAM, Mass. & SALISBURY, England, March 04, 2026--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted one newly-hired employee inducement options to purchase an aggregate of 6,750 shares of KalVista common stock on March 1, 2026 as inducements material to such employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on th
Yahoo · Mar 2, 2026
FRAMINGHAM, Mass. & SALISBURY, England, March 02, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and the Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session. The presentations demonstrate a significant shift in how patients manage hereditary angioedema (HAE) attacks when provided with access to
Benzinga · Mar 2, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KALV.
